<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00345969</url>
  </required_header>
  <id_info>
    <org_study_id>HSC 02-1108</org_study_id>
    <nct_id>NCT00345969</nct_id>
  </id_info>
  <brief_title>Exercise and Testosterone Therapy in Elderly Men With Physical Frailty</brief_title>
  <official_title>Exercise and Testosterone Therapy in Elderly Men With Physical Frailty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Solvay Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to determine, in hypogonadal older men with physical
      frailty, whether exercise training combined with testosterone replacement therapy can improve
      skeletal muscle strength, and lean mass, to a greater degree than exercise training alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Decreases in physical abilities, including losses of strength, endurance, balance, and
      coordination are major causes of disability and loss of independence in older men. Such
      individuals are at high risk for injurious falls, hospitalization, and use of supportive
      services. Age-associated testosterone deficiency may contribute to deficits in muscle mass
      and strength that are common in this patient population.

      The primary aim of this study is to determine, in hypogonadal older men with physical
      frailty, whether six months of exercise training combined with testosterone replacement
      therapy can improve skeletal muscle mass and skeletal muscle strength, to a greater degree
      than six months of exercise training alone.

      Secondary study aims are to determine in hypogonadal older men with physical frailty, whether
      six months of exercise training combined with testosterone replacement therapy can improve
      physical function, bone mineral density, and quality of life, to a greater degree than six
      months of exercise training alone.

      Comparison: Men age 65 years and older who meet criteria for physical frailty and have a
      serum testosterone level below 350 ng/dl are randomly assigned to one of two groups: 1)
      transdermal testosterone replacement therapy + supervised exercise training for six months
      vs. 2) inactive placebo gel + supervised exercise training for six months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Total Lean Body Mass</measure>
    <time_frame>Baseline and Six Months</time_frame>
    <description>Total Lean Mass measured by Dual X-ray Absorptiometry (DXA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Skeletal Muscle Strength by 1-RM</measure>
    <time_frame>Baseline and Six Months</time_frame>
    <description>One-repetition maximum strength for leg extension</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Isokinetic Leg Extension Torque at 0 Deg/Sec</measure>
    <time_frame>Baseline and Six Months</time_frame>
    <description>Leg Extension Torque measured with Cybex dynamometer at 0 deg/sec</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Leg Extension Torque at 60 Deg/Sec</measure>
    <time_frame>Baseline and Six Months</time_frame>
    <description>Leg Extension Torque measured with Cybex dynamometry at 60 deg/sec</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Body Fat Mass</measure>
    <time_frame>Baseline and Six Months</time_frame>
    <description>Total Body Fat Mass as measured by DXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Femoral Bone Mineral Density (BMD)</measure>
    <time_frame>Baseline and Six Months</time_frame>
    <description>Femoral Bone Mineral Density measured with Dual X-ray Absorptiometry (DXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Modified Physical Performance (mPPT) Score</measure>
    <time_frame>Baseline and Six Months</time_frame>
    <description>The Modified Physical Performance Test (mPPT) is a direct observational test that assesses multiple dimensions of physical function (basic and complex activities of daily living [ADL]) with different levels of difficulty. The test consists of 9 performance tasks. The total score range is 0-36 (min-max), with higher scores indicating better performance. Sub-scores are assigned for each of 9 item tasks; sub-score range is 0-4 (min-max) with higher scores indicating better performance. The sub-scores are summed to compute the total score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Testosterone Level</measure>
    <time_frame>Baseline and Six Months</time_frame>
    <description>Total Serum Testosterone Level (ng/mL)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Serum Prostate Specific Antigen (PSA) Level</measure>
    <time_frame>Baseline and Six Months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Hematocrit</measure>
    <time_frame>Baseline and Six Months</time_frame>
    <description>Percentage of the volume of whole blood composed of Red Blood Cells</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum Total Cholesterol Level</measure>
    <time_frame>Baseline and Six Months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum HDL Cholesterol Level</measure>
    <time_frame>Baseline and Six Months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum LDL Cholesterol Level</measure>
    <time_frame>Baseline and Six Months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Physical Frailty</condition>
  <condition>Hip Fracture</condition>
  <condition>Elective Hip Replacement</condition>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Transdermal Testosterone gel (1%)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transdermal testosterone 1% gel (Androgel) provided as 2.5 gm and/or 5 gm gel packets with dose titration and monthly dose adjustments to achieve and maintain serum total testosterone level between 500-900 mg/dL. Gel to be applied daily by participants. Participants are blinded to the contents of the gel packets. Participants in this arm also perform supervised exercise training for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inactive topical gel identical in appearance to the active medication, provided in packets identical to the packaging for the active medication. Gel to be applied daily by participants. Participants are blinded to the contents of the gel packets. Participants in this arm also perform supervised exercise training for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal Testosterone gel (1%)</intervention_name>
    <description>Transdermal testosterone replacement therapy with Androgel(TM). Daily application of gel at 5 mg, 7.5 gm, or 10 gm for six months. Target serum total testosterone level between 500-900 ng/dl.</description>
    <arm_group_label>Transdermal Testosterone gel (1%)</arm_group_label>
    <other_name>Androgel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Supervised exercise training</intervention_name>
    <description>Supervised exercise training performed on site at academic medical center exercise facility. Exercise training consisted of 2 months of flexibility, balance, treadmill walking, and physical therapy-type exercises, followed by 4 months of progressive resistance training.</description>
    <arm_group_label>Transdermal Testosterone gel (1%)</arm_group_label>
    <arm_group_label>Placebo gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male, age 65 years and older

          -  Total serum testosterone level &lt; 350 ng/dl

          -  Total Modified Physical Performance Test Score &lt;28

        Exclusion Criteria:

          -  Inability to walk 50 feet independently

          -  Current use of estrogen, progestin, or androgen containing compound

          -  Diagnosis of dementia of severity sufficient to interfere with informed consent or
             compliance with the protocol, or a score of 11 or greater on the Short Blessed Test of
             Orientation, Memory and Concentration

          -  Visual or hearing impairments that interfere with following directions

          -  Cardiopulmonary disease (recent MI, unstable angina or CHF, etc.), neuromuscular
             impairments, or unstable medical condition that would contraindicate progressive
             resistance exercise training

          -  History of prostate cancer or hormone dependent neoplasia

          -  PSA level &gt; 4 ng/ml

          -  Serum liver transaminase levels of greater than 2 standard deviations above normal

          -  Use of drugs for osteoporosis for less than 1 year

          -  Current participation in a vigorous exercise or weight-training program more than once
             per week

          -  History of sleep apnea requiring use of CPAP

          -  Uncontrolled thyroid disease

          -  Diagnosis of cancer within the past 5 years other than superficial skin cancer
             (squamous or basal cell)

          -  hematocrit &gt; 50%

          -  AUA symptom score &gt; 16.

          -  History of alcohol or substance abuse

          -  Presence of severe facial acne

          -  Active symptoms of depression with GDS score &gt; 5 and symptoms severe enough to cause
             &gt;5% weight loss in previous 3 months or interfere with research assessments
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ellen F. Binder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2006</study_first_submitted>
  <study_first_submitted_qc>June 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2006</study_first_posted>
  <results_first_submitted>January 15, 2016</results_first_submitted>
  <results_first_submitted_qc>January 22, 2018</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 21, 2018</results_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Ellen F. Binder, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Testosterone Replacement Therapy</keyword>
  <keyword>Physical Frailty</keyword>
  <keyword>Hip Fracture</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hip Fractures</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from orthopedic units of local hospitals, rehabilitation facilities (both acute rehabilitation units and SNFs), home care programs, and the community-at-large.</recruitment_details>
      <pre_assignment_details>Participants were carefully screened for exclusion criteria prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Exercise + Placebo</title>
          <description>Participants assigned to this group were prescribed an inactive topical gel for 6 months, and also performed a supervised exercise training program three times per week for 6 months.</description>
        </group>
        <group group_id="P2">
          <title>Exercise + Testosterone</title>
          <description>Participants assigned to this group were prescribed transdermal testosterone (Androgel 1%) for six months, and performed a supervised exercise training program three times per week for six months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Men who completed the intervention and provided baseline and follow-up data for primary outcome measures.</population>
      <group_list>
        <group group_id="B1">
          <title>Exercise + Placebo</title>
          <description>Participants assigned to this group were prescribed an inactive topical gel for 6 months, and also performed a supervised exercise training program three times per week for 6 months.</description>
        </group>
        <group group_id="B2">
          <title>Exercise + Testosterone</title>
          <description>Participants assigned to this group were prescribed transdermal testosterone (Androgel 1%) for six months, and performed a supervised exercise training program three times per week for six months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81" spread="4"/>
                    <measurement group_id="B2" value="77" spread="6"/>
                    <measurement group_id="B3" value="80" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Modified Physical Performance (mPPT) score</title>
          <description>Range 0-36, (min-max); higher scores indicate better physical performance. The Total mPPT score is constructed by summing sub-scores of 9 performance tasks. Sub-scores have a range of 0-4 (min-max); higher sub-scores indicate better performance.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23" spread="4"/>
                    <measurement group_id="B2" value="26" spread="3"/>
                    <measurement group_id="B3" value="25" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Testosterone level (ng/dL)</title>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="252" spread="71"/>
                    <measurement group_id="B2" value="248" spread="97"/>
                    <measurement group_id="B3" value="250" spread="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (kg/m2)</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="3"/>
                    <measurement group_id="B2" value="29" spread="5"/>
                    <measurement group_id="B3" value="29" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight (lbs.)</title>
          <units>lbs.</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="193" spread="30"/>
                    <measurement group_id="B2" value="195" spread="38"/>
                    <measurement group_id="B3" value="194" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Total Lean Body Mass</title>
        <description>Total Lean Mass measured by Dual X-ray Absorptiometry (DXA)</description>
        <time_frame>Baseline and Six Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exercise + Placebo</title>
            <description>Participants assigned to this group were prescribed an inactive topical gel for 6 months, and also performed a supervised exercise training program three times per week for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Exercise + Testosterone</title>
            <description>Participants assigned to this group were prescribed transdermal testosterone (Androgel 1%) for six months, and performed a supervised exercise training program three times per week for six months.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Total Lean Body Mass</title>
          <description>Total Lean Mass measured by Dual X-ray Absorptiometry (DXA)</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.8"/>
                    <measurement group_id="O2" value="2.3" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Skeletal Muscle Strength by 1-RM</title>
        <description>One-repetition maximum strength for leg extension</description>
        <time_frame>Baseline and Six Months</time_frame>
        <population>Only 8 participants in the Exercise+Testosterone group provided Leg Extension 1-RM measurements at baseline and 6-month follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Exercise + Placebo</title>
            <description>Participants assigned to this group were prescribed an inactive topical gel for 6 months, and also performed a supervised exercise training program three times per week for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Exercise + Testosterone</title>
            <description>Participants assigned to this group were prescribed transdermal testosterone (Androgel 1%) for six months, and performed a supervised exercise training program three times per week for six months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Skeletal Muscle Strength by 1-RM</title>
          <description>One-repetition maximum strength for leg extension</description>
          <population>Only 8 participants in the Exercise+Testosterone group provided Leg Extension 1-RM measurements at baseline and 6-month follow-up.</population>
          <units>lbs.</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.2" spread="33.3"/>
                    <measurement group_id="O2" value="70.3" spread="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.55</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Isokinetic Leg Extension Torque at 0 Deg/Sec</title>
        <description>Leg Extension Torque measured with Cybex dynamometer at 0 deg/sec</description>
        <time_frame>Baseline and Six Months</time_frame>
        <population>Only 10 participants in Exercise+Placebo group, and 8 participants in Exercise+Testosterone group, provided Leg Extension torque measurements at baseline and 6-month follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Exercise + Placebo</title>
            <description>Participants assigned to this group were prescribed an inactive topical gel for 6 months, and also performed a supervised exercise training program three times per week for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Exercise + Testosterone</title>
            <description>Participants assigned to this group were prescribed transdermal testosterone (Androgel 1%) for six months, and performed a supervised exercise training program three times per week for six months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Isokinetic Leg Extension Torque at 0 Deg/Sec</title>
          <description>Leg Extension Torque measured with Cybex dynamometer at 0 deg/sec</description>
          <population>Only 10 participants in Exercise+Placebo group, and 8 participants in Exercise+Testosterone group, provided Leg Extension torque measurements at baseline and 6-month follow-up.</population>
          <units>ft/lb</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" spread="14.2"/>
                    <measurement group_id="O2" value="19.8" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.23</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Leg Extension Torque at 60 Deg/Sec</title>
        <description>Leg Extension Torque measured with Cybex dynamometry at 60 deg/sec</description>
        <time_frame>Baseline and Six Months</time_frame>
        <population>Only 10 participants in the Exercise+Placebo group, and 8 participants in the Exercise+Testosterone group, provided Leg extension torque measurements at baseline and 6 month follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Exercise + Placebo</title>
            <description>Participants assigned to this group were prescribed an inactive topical gel for 6 months, and also performed a supervised exercise training program three times per week for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Exercise + Testosterone</title>
            <description>Participants assigned to this group were prescribed transdermal testosterone (Androgel 1%) for six months, and performed a supervised exercise training program three times per week for six months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Leg Extension Torque at 60 Deg/Sec</title>
          <description>Leg Extension Torque measured with Cybex dynamometry at 60 deg/sec</description>
          <population>Only 10 participants in the Exercise+Placebo group, and 8 participants in the Exercise+Testosterone group, provided Leg extension torque measurements at baseline and 6 month follow-up.</population>
          <units>ft/lb</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="13.5"/>
                    <measurement group_id="O2" value="19.4" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.43</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Body Fat Mass</title>
        <description>Total Body Fat Mass as measured by DXA</description>
        <time_frame>Baseline and Six Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exercise + Placebo</title>
            <description>Participants assigned to this group were prescribed an inactive topical gel for 6 months, and also performed a supervised exercise training program three times per week for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Exercise + Testosterone</title>
            <description>Participants assigned to this group were prescribed transdermal testosterone (Androgel 1%) for six months, and performed a supervised exercise training program three times per week for six months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Body Fat Mass</title>
          <description>Total Body Fat Mass as measured by DXA</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="0.96"/>
                    <measurement group_id="O2" value="-1.1" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.33</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Femoral Bone Mineral Density (BMD)</title>
        <description>Femoral Bone Mineral Density measured with Dual X-ray Absorptiometry (DXA)</description>
        <time_frame>Baseline and Six Months</time_frame>
        <population>Only 10 participants in the Exercise+Placebo group, and 10 participants in the Exercise+Testosterone group, provided femoral bone density measurements at baseline and the 6 month follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Exercise + Placebo</title>
            <description>Participants assigned to this group were prescribed an inactive topical gel for 6 months, and also performed a supervised exercise training program three times per week for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Exercise + Testosterone</title>
            <description>Participants assigned to this group were prescribed transdermal testosterone (Androgel 1%) for six months, and performed a supervised exercise training program three times per week for six months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Femoral Bone Mineral Density (BMD)</title>
          <description>Femoral Bone Mineral Density measured with Dual X-ray Absorptiometry (DXA)</description>
          <population>Only 10 participants in the Exercise+Placebo group, and 10 participants in the Exercise+Testosterone group, provided femoral bone density measurements at baseline and the 6 month follow-up.</population>
          <units>g/cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.008" spread="1.238"/>
                    <measurement group_id="O2" value="0.084" spread="3.515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.93</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Modified Physical Performance (mPPT) Score</title>
        <description>The Modified Physical Performance Test (mPPT) is a direct observational test that assesses multiple dimensions of physical function (basic and complex activities of daily living [ADL]) with different levels of difficulty. The test consists of 9 performance tasks. The total score range is 0-36 (min-max), with higher scores indicating better performance. Sub-scores are assigned for each of 9 item tasks; sub-score range is 0-4 (min-max) with higher scores indicating better performance. The sub-scores are summed to compute the total score.</description>
        <time_frame>Baseline and Six Months</time_frame>
        <population>Only 10 participants in the Exercise+Placebo group, and 9 participants in the Exercise+Testosterone group, provided baseline and follow-up mPPT measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Exercise + Placebo</title>
            <description>Participants assigned to this group were prescribed an inactive topical gel for 6 months, and also performed a supervised exercise training program three times per week for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Exercise + Testosterone</title>
            <description>Participants assigned to this group were prescribed transdermal testosterone (Androgel 1%) for six months, and performed a supervised exercise training program three times per week for six months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Modified Physical Performance (mPPT) Score</title>
          <description>The Modified Physical Performance Test (mPPT) is a direct observational test that assesses multiple dimensions of physical function (basic and complex activities of daily living [ADL]) with different levels of difficulty. The test consists of 9 performance tasks. The total score range is 0-36 (min-max), with higher scores indicating better performance. Sub-scores are assigned for each of 9 item tasks; sub-score range is 0-4 (min-max) with higher scores indicating better performance. The sub-scores are summed to compute the total score.</description>
          <population>Only 10 participants in the Exercise+Placebo group, and 9 participants in the Exercise+Testosterone group, provided baseline and follow-up mPPT measurements.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="3.7"/>
                    <measurement group_id="O2" value="2.8" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum Prostate Specific Antigen (PSA) Level</title>
        <time_frame>Baseline and Six Months</time_frame>
        <population>Only 10 participants in the Exercise+Placebo group, and 9 participants in the Exercise+Testosterone group, provided serum PSA level measurements at baseline and 6 month follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Exercise + Placebo</title>
            <description>Participants assigned to this group were prescribed an inactive topical gel for 6 months, and also performed a supervised exercise training program three times per week for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Exercise + Testosterone</title>
            <description>Participants assigned to this group were prescribed transdermal testosterone (Androgel 1%) for six months, and performed a supervised exercise training program three times per week for six months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Prostate Specific Antigen (PSA) Level</title>
          <population>Only 10 participants in the Exercise+Placebo group, and 9 participants in the Exercise+Testosterone group, provided serum PSA level measurements at baseline and 6 month follow-up.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.27"/>
                    <measurement group_id="O2" value="0.21" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.49</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Hematocrit</title>
        <description>Percentage of the volume of whole blood composed of Red Blood Cells</description>
        <time_frame>Baseline and Six Months</time_frame>
        <population>Only 10 participants in the Exercise+Placebo group, and 9 participants in the Exercise+Testosterone group, provided hematocrit measurements at baseline and 6-month follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Exercise + Placebo</title>
            <description>Participants assigned to this group were prescribed an inactive topical gel for 6 months, and also performed a supervised exercise training program three times per week for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Exercise + Testosterone</title>
            <description>Participants assigned to this group were prescribed transdermal testosterone (Androgel 1%) for six months, and performed a supervised exercise training program three times per week for six months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hematocrit</title>
          <description>Percentage of the volume of whole blood composed of Red Blood Cells</description>
          <population>Only 10 participants in the Exercise+Placebo group, and 9 participants in the Exercise+Testosterone group, provided hematocrit measurements at baseline and 6-month follow-up.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="2.6"/>
                    <measurement group_id="O2" value="2.5" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum Total Cholesterol Level</title>
        <time_frame>Baseline and Six Months</time_frame>
        <population>Only 9 participants in the Exercise+Placebo group, and 9 participants in the Exercise+Testosterone group, provided serum for cholesterol measurements at baseline and 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Exercise + Placebo</title>
            <description>Participants assigned to this group were prescribed an inactive topical gel for 6 months, and also performed a supervised exercise training program three times per week for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Exercise + Testosterone</title>
            <description>Participants assigned to this group were prescribed transdermal testosterone (Androgel 1%) for six months, and performed a supervised exercise training program three times per week for six months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Total Cholesterol Level</title>
          <population>Only 9 participants in the Exercise+Placebo group, and 9 participants in the Exercise+Testosterone group, provided serum for cholesterol measurements at baseline and 6 months.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="15.4"/>
                    <measurement group_id="O2" value="-9.0" spread="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.71</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum HDL Cholesterol Level</title>
        <time_frame>Baseline and Six Months</time_frame>
        <population>Only 9 participants in the Exercise+Placebo group, and 9 participants in the Exercise+Testosterone group, provided serum for HDL cholesterol measurements at baseline and 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Exercise + Placebo</title>
            <description>Participants assigned to this group were prescribed an inactive topical gel for 6 months, and also performed a supervised exercise training program three times per week for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Exercise + Testosterone</title>
            <description>Participants assigned to this group were prescribed transdermal testosterone (Androgel 1%) for six months, and performed a supervised exercise training program three times per week for six months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum HDL Cholesterol Level</title>
          <population>Only 9 participants in the Exercise+Placebo group, and 9 participants in the Exercise+Testosterone group, provided serum for HDL cholesterol measurements at baseline and 6 months.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="9.0"/>
                    <measurement group_id="O2" value="1.7" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.44</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum LDL Cholesterol Level</title>
        <time_frame>Baseline and Six Months</time_frame>
        <population>Only 9 participants in the Exercise+Placebo group, and 9 participants in the Exercise+Testosterone group, provided serum for LDL cholesterol measurements at baseline and 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Exercise + Placebo</title>
            <description>Participants assigned to this group were prescribed an inactive topical gel for 6 months, and also performed a supervised exercise training program three times per week for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Exercise + Testosterone</title>
            <description>Participants assigned to this group were prescribed transdermal testosterone (Androgel 1%) for six months, and performed a supervised exercise training program three times per week for six months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum LDL Cholesterol Level</title>
          <population>Only 9 participants in the Exercise+Placebo group, and 9 participants in the Exercise+Testosterone group, provided serum for LDL cholesterol measurements at baseline and 6 months.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="15.3"/>
                    <measurement group_id="O2" value="-1.6" spread="39.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.89</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Testosterone Level</title>
        <description>Total Serum Testosterone Level (ng/mL)</description>
        <time_frame>Baseline and Six Months</time_frame>
        <population>Only 9 participants in the Exercise+Testosterone group provided serum testosterone levels at baseline and 6-month follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Exercise + Placebo</title>
            <description>Participants assigned to this group were prescribed an inactive topical gel for 6 months, and also performed a supervised exercise training program three times per week for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Exercise + Testosterone</title>
            <description>Participants assigned to this group were prescribed transdermal testosterone (Androgel 1%) for six months, and performed a supervised exercise training program three times per week for six months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Testosterone Level</title>
          <description>Total Serum Testosterone Level (ng/mL)</description>
          <population>Only 9 participants in the Exercise+Testosterone group provided serum testosterone levels at baseline and 6-month follow-up.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.3" spread="72.6"/>
                    <measurement group_id="O2" value="121.2" spread="235.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Exercise + Placebo</title>
          <description>Participants assigned to this group were prescribed an inactive topical gel for 6 months, and also performed a supervised exercise training program three times per week for 6 months.</description>
        </group>
        <group group_id="E2">
          <title>Exercise + Testosterone</title>
          <description>Participants assigned to this group were prescribed transdermal testosterone (Androgel 1%) for six months, and performed a supervised exercise training program three times per week for six months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <description>Participant experienced new onset atrial fibrillation that required acute care hospitalization. The patient's symptoms occurred at rest and were not coincident with performing exercise.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Participant experienced a fall during balance testing; no injury sustained.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated serum PSA level</sub_title>
                <description>Participant had elevated PSA level (7.2 ng/mL) at month 6 of study, which returned to normal at 30-day follow up.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small number of subjects enrolled, single site trial, included both hip fracture patients and a few patients with elective hip joint replacement.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ellen F. Binder, MD</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-286-2707</phone>
      <email>ebinder@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

